NCT05168904View on ClinicalTrials.gov

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
LeukemiaMyelodysplastic Syndrome(MDS)
Interventions
DRUG

fadraciclib

Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.

Trial Locations (2)

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT05168904 - A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter